Top

Pituitary

Published in:

Open Access 26-04-2022 | Cushing's Syndrome

Glucocorticoid Withdrawal Syndrome following treatment of endogenous Cushing Syndrome

Authors: Xin He, James W. Findling, Richard J. Auchus

Published in: Pituitary | Issue 3/2022

Abstract

Purpose:

Literature regarding endogenous Cushing syndrome (CS) largely focuses on the challenges of diagnosis, subtyping, and treatment. The enigmatic phenomenon of glucocorticoid withdrawal syndrome (GWS), due to rapid reduction in cortisol exposure following treatment of CS, is less commonly discussed but also difficult to manage. We highlight the clinical approach to navigating patients from GWS and adrenal insufficiency to full hypothalamic-pituitary-adrenal (HPA) axis recovery.

Methods:

We review the literature on the pathogenesis of GWS and its clinical presentation. We provide strategies for glucocorticoid dosing and tapering, HPA axis testing, as well as pharmacotherapy and ancillary treatments for GWS symptom management.

Results:

GWS can be difficult to differentiate from adrenal insufficiency and CS recurrence, which complicates glucocorticoid dosing and tapering regimens. Monitoring for HPA axis recovery requires both clinical and biochemical assessments. The most important intervention is reassurance to patients that GWS symptoms portend a favorable prognosis of sustained remission from CS, and GWS typically resolves as the HPA axis recovers. GWS also occurs during medical management of CS, and gradual dose titration based primarily on symptoms is essential to maintain adherence and to eventually achieve disease control. Myopathy and neurocognitive dysfunction can be chronic complications of CS that do not completely recover.

Conclusions:

Due to limited data, no guidelines have been developed for management of GWS. Nevertheless, this article provides overarching themes derived from published literature plus expert opinion and experience. Future studies are needed to better understand the pathophysiology of GWS to guide more targeted and optimal treatments.

Available only for authorised users

Carroll TB, Findling JW (2010) The diagnosis of Cushing’s syndrome. Rev Endocr Metab Disord 11:147–153. https://doi.org/10.1007/s11154-010-9143-3CrossRefPubMed

Fleseriu M, Auchus R, Bancos I et al (2021) Consensus on diagnosis and management of Cushing’s disease: a guideline update. Lancet Diabetes Endocrinol 9:847–875. https://doi.org/10.1016/S2213-8587(21)00235-7CrossRefPubMed

Nieman LK, Biller BMK, Findling JW et al (2015) Treatment of Cushing’s Syndrome: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 100:2807–2831. https://doi.org/10.1210/jc.2015-1818CrossRefPubMedPubMedCentral

Biller BMK, Grossman AB, Stewart PM et al (2008) Treatment of adrenocorticotropin-dependent Cushing’s syndrome: a consensus statement. J Clin Endocrinol Metab 93:2454–2462. https://doi.org/10.1210/jc.2007-2734CrossRefPubMedPubMedCentral

Geer EB, Shafiq I, Gordon MB et al (2017) BIOCHEMICAL CONTROL DURING LONG-TERM FOLLOW-UP OF 230 ADULT PATIENTS WITH CUSHING DISEASE: A MULTICENTER RETROSPECTIVE STUDY. Endocr Pract 23:962–970. https://doi.org/10.4158/EP171787.ORCrossRefPubMed

Colao A, Petersenn S, Newell-Price J et al (2012) A 12-Month Phase 3 Study of Pasireotide in Cushing’s Disease. N Engl J Med 366:914–924. https://doi.org/10.1056/NEJMoa1105743CrossRefPubMed

Lacroix A, Gu F, Gallardo W et al (2018) Efficacy and safety of once-monthly pasireotide in Cushing’s disease: a 12 month clinical trial. Lancet Diabetes Endocrinol 6:17–26. https://doi.org/10.1016/S2213-8587(17)30326-1CrossRefPubMed

Pivonello R, De Martino MC, Cappabianca P et al (2009) The medical treatment of Cushing’s disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery. J Clin Endocrinol Metab 94:223–230. https://doi.org/10.1210/jc.2008-1533CrossRefPubMed

Pivonello R, Fleseriu M, Newell-Price J et al (2020) Efficacy and safety of osilodrostat in patients with Cushing’s disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase. Lancet Diabetes Endocrinol 8:748–761. https://doi.org/10.1016/S2213-8587(20)30240-0CrossRefPubMed

10.

Ceccato F, Zilio M, Barbot M et al (2018) Metyrapone treatment in Cushing’s syndrome: a real-life study. Endocrine 62:701–711. https://doi.org/10.1007/s12020-018-1675-4CrossRefPubMed

11.

Fleseriu M, Pivonello R, Elenkova A et al (2019) Efficacy and safety of levoketoconazole in the treatment of endogenous Cushing’s syndrome (SONICS): a phase 3, multicentre, open-label, single-arm trial. Lancet Diabetes Endocrinol 7:855–865. https://doi.org/10.1016/S2213-8587(19)30313-4CrossRefPubMed

12.

Castinetti F, Guignat L, Giraud P et al (2014) Ketoconazole in Cushing’s disease: is it worth a try? J Clin Endocrinol Metab 99:1623–1630. https://doi.org/10.1210/jc.2013-3628CrossRefPubMed

13.

Fleseriu M, Biller BMK, Findling JW et al (2012) Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing’s syndrome. J Clin Endocrinol Metab 97:2039–2049. https://doi.org/10.1210/jc.2011-3350CrossRefPubMed

14.

Reincke M, Albani A, Assie G et al (2021) Corticotroph tumor progression after bilateral adrenalectomy (Nelson’s syndrome): systematic review and expert consensus recommendations. Eur J Endocrinol 184:P1–P16. https://doi.org/10.1530/EJE-20-1088CrossRefPubMedPubMedCentral

15.

Lindsay JR, Oldfield EH, Stratakis CA, Nieman LK (2011) The Postoperative Basal Cortisol and CRH Tests for Prediction of Long-Term Remission from Cushing’s Disease after Transsphenoidal Surgery. J Clin Endocrinol Metab 96:2057–2064. https://doi.org/10.1210/jc.2011-0456CrossRefPubMedPubMedCentral

16.

Hameed N, Yedinak CG, Brzana J et al (2013) Remission rate after transsphenoidal surgery in patients with pathologically confirmed Cushing’s disease, the role of cortisol, ACTH assessment and immediate reoperation: a large single center experience. Pituitary 16:452–458. https://doi.org/10.1007/s11102-012-0455-zCrossRefPubMed

17.

Ramm-Pettersen J, Halvorsen H, Evang JA et al (2015) Low immediate postoperative serum-cortisol nadir predicts the short-term, but not long-term, remission after pituitary surgery for Cushing’s disease. BMC Endocr Disord 15:62. https://doi.org/10.1186/s12902-015-0055-9CrossRefPubMedPubMedCentral

18.

Ironside N, Chatain G, Asuzu D et al (2018) Earlier post-operative hypocortisolemia may predict durable remission from Cushing’s disease. Eur J Endocrinol 178:255–263. https://doi.org/10.1530/EJE-17-0873CrossRefPubMedPubMedCentral

19.

Hochberg Z, Pacak K, Chrousos GP (2003) Endocrine Withdrawal Syndromes. Endocr Rev 24:523–538. https://doi.org/10.1210/er.2001-0014CrossRefPubMed

20.

Dixon RB, Christy NP (1980) On the various forms of corticosteroid withdrawal syndrome. Am J Med 68:224–230. https://doi.org/10.1016/0002-9343(80)90358-7CrossRefPubMed

21.

AMATRUDA TT ND JR (1965) Certain Endocrine and Metabolic Facets of the Steroid Withdrawal Syndrome. J Clin Endocrinol Metab 25:1207–1217. https://doi.org/10.1210/jcem-25-9-1207CrossRefPubMed

22.

Dorn LD, Burgess ES, Friedman TC et al (1997) The Longitudinal Course of Psychopathology in Cushing’s Syndrome after Correction of Hypercortisolism. J Clin Endocrinol Metab 82:912–919. https://doi.org/10.1210/jcem.82.3.3834CrossRefPubMed

23.

Chrousos GP, Gold PW (1992) The Concepts of Stress and Stress System Disorders: Overview of Physical and Behavioral Homeostasis. JAMA 267:1244–1252. https://doi.org/10.1001/jama.1992.03480090092034CrossRefPubMed

24.

Kling MA, Roy A, Doran AR et al (1991) Cerebrospinal fluid immunoreactive corticotropin-releasing hormone and adrenocorticotropin secretion in Cushing’s disease and major depression: potential clinical implications. J Clin Endocrinol Metab 72:260–271. https://doi.org/10.1210/jcem-72-2-260CrossRefPubMed

25.

Gomez MT, Magiakou MA, Mastorakos G, Chrousos GP (1993) The pituitary corticotroph is not the rate limiting step in the postoperative recovery of the hypothalamic-pituitary-adrenal axis in patients with Cushing syndrome. J Clin Endocrinol Metab 77:173–177. https://doi.org/10.1210/jcem.77.1.8392083CrossRefPubMed

26.

Young EA, Kwak SP, Kottak J (1995) Negative feedback regulation following administration of chronic exogenous corticosterone. J Neuroendocrinol 7:37–45. https://doi.org/10.1111/j.1365-2826.1995.tb00665.xCrossRefPubMed

27.

Papanicolaou DA, Tsigos C, Oldfield EH, Chrousos GP (1996) Acute glucocorticoid deficiency is associated with plasma elevations of interleukin-6: does the latter participate in the symptomatology of the steroid withdrawal syndrome and adrenal insufficiency? J Clin Endocrinol Metab 81:2303–2306. https://doi.org/10.1210/jcem.81.6.8964868CrossRefPubMed

28.

Ciric I, Zhao J-C, Du H et al (2012) Transsphenoidal surgery for Cushing disease: experience with 136 patients. Neurosurgery 70:70–80 discussion 80–81. https://doi.org/10.1227/NEU.0b013e31822dda2cCrossRefPubMed

29.

Alexandraki KI, Kaltsas GA, Isidori AM et al (2013) Long-term remission and recurrence rates in Cushing’s disease: predictive factors in a single-centre study. Eur J Endocrinol 168:639–648. https://doi.org/10.1530/EJE-12-0921CrossRefPubMed

30.

Capatina C, Hinojosa-Amaya JM, Poiana C, Fleseriu M (2020) Management of patients with persistent or recurrent Cushing’s disease after initial pituitary surgery. Expert Rev Endocrinol Metab 15:321–339. https://doi.org/10.1080/17446651.2020.1802243CrossRefPubMed

31.

Stroud A, Dhaliwal P, Alvarado R et al (2020) Outcomes of pituitary surgery for Cushing’s disease: a systematic review and meta-analysis. Pituitary 23:595–609. https://doi.org/10.1007/s11102-020-01066-8CrossRefPubMed

32.

Acree R, Miller CM, Abel BS et al (2021) Patient and Provider Perspectives on Postsurgical Recovery of Cushing Syndrome. J Endocr Soc 5:bvab109. https://doi.org/10.1210/jendso/bvab109CrossRefPubMedPubMedCentral

33.

AbdelMannan D, Selman WR, Arafah BM (2010) Peri-operative management of Cushing’s disease. Rev Endocr Metab Disord 11:127–134. https://doi.org/10.1007/s11154-010-9140-6CrossRefPubMed

34.

Costenaro F, Rodrigues TC, Rollin GAF et al (2014) Evaluation of Cushing’s disease remission after transsphenoidal surgery based on early serum cortisol dynamics. Clin Endocrinol (Oxf) 80:411–418. https://doi.org/10.1111/cen.12300CrossRef

35.

Varlamov EV, Vila G, Fleseriu M (2022) Perioperative Management of a Patient With Cushing Disease. J Endocr Soc 6:bvac010. https://doi.org/10.1210/jendso/bvac010CrossRefPubMedPubMedCentral

36.

El Asmar N, Rajpal A, Selman WR, Arafah BM (2018) The Value of Perioperative Levels of ACTH, DHEA, and DHEA-S and Tumor Size in Predicting Recurrence of Cushing Disease. J Clin Endocrinol Metab 103:477–485. https://doi.org/10.1210/jc.2017-01797CrossRefPubMed

37.

DeLozier OM, Dream SY, Findling JW et al (2022) Selective Glucocorticoid Replacement Following Unilateral Adrenalectomy for Hypercortisolism and Primary Aldosteronism. J Clin Endocrinol Metab 107:e538–e547. https://doi.org/10.1210/clinem/dgab698CrossRefPubMed

38.

Stuijver DJF, van Zaane B, Feelders RA et al (2011) Incidence of venous thromboembolism in patients with Cushing’s syndrome: a multicenter cohort study. J Clin Endocrinol Metab 96:3525–3532. https://doi.org/10.1210/jc.2011-1661CrossRefPubMed

39.

van der Pas R, Leebeek FWG, Hofland LJ et al (2013) Hypercoagulability in Cushing’s syndrome: prevalence, pathogenesis and treatment. Clin Endocrinol (Oxf) 78:481–488. https://doi.org/10.1111/cen.12094CrossRef

40.

van der Pas R, de Bruin C, Leebeek FWG et al (2012) The hypercoagulable state in Cushing’s disease is associated with increased levels of procoagulant factors and impaired fibrinolysis, but is not reversible after short-term biochemical remission induced by medical therapy. J Clin Endocrinol Metab 97:1303–1310. https://doi.org/10.1210/jc.2011-2753CrossRefPubMed

41.

Kristof RA, Rother M, Neuloh G, Klingmüller D (2009) Incidence, clinical manifestations, and course of water and electrolyte metabolism disturbances following transsphenoidal pituitary adenoma surgery: a prospective observational study: Clinical article. J Neurosurg 111:555–562. https://doi.org/10.3171/2008.9.JNS08191CrossRefPubMed

42.

Yuen KCJ, Ajmal A, Correa R, Little AS (2019) Sodium Perturbations After Pituitary Surgery. Neurosurg Clin 30:515–524. https://doi.org/10.1016/j.nec.2019.05.011CrossRef

43.

Ghiam MK, Chyou DE, Dable CL et al (2021) 30-Day Readmissions and Coordination of Care Following Endoscopic Transsphenoidal Pituitary Surgery: Experience with 409 Patients. J Neurol Surg Part B Skull Base. https://doi.org/10.1055/s-0041-1729980CrossRef

44.

Bohl MA, Ahmad S, Jahnke H et al (2016) Delayed Hyponatremia Is the Most Common Cause of 30-Day Unplanned Readmission After Transsphenoidal Surgery for Pituitary Tumors. Neurosurgery 78:84–90. https://doi.org/10.1227/NEU.0000000000001003CrossRefPubMed

45.

Doherty GM, Nieman LK, Cutler GB et al (1990) Time to recovery of the hypothalamic-pituitary-adrenal axis after curative resection of adrenal tumors in patients with Cushing’s syndrome. Surgery 108:1085–1090PubMed

46.

Sippel RS, Elaraj DM, Kebebew E et al (2008) Waiting for change: Symptom resolution after adrenalectomy for Cushing’s syndrome. Surgery 144:1054–1061. https://doi.org/10.1016/j.surg.2008.08.024CrossRefPubMed

47.

Derendorf H, Möllmann H, Barth J et al (1991) Pharmacokinetics and Oral Bioavailability of Hydrocortisone. J Clin Pharmacol 31:473–476. https://doi.org/10.1002/j.1552-4604.1991.tb01906.xCrossRefPubMed

48.

Suzuki K, Nonaka K, Ichihara K et al (1986) Hypercalcemia in Glucocorticoid Withdrawal. Endocrinol Jpn 33:203–209. https://doi.org/10.1507/endocrj1954.33.203CrossRefPubMed

49.

Oyama Y, Iwafuchi Y, Narita I (2021) A case of hypercalcemia because of adrenal insufficiency induced by glucocorticoid withdrawal in a patient undergoing hemodialysis. CEN Case Rep. https://doi.org/10.1007/s13730-021-00619-5CrossRefPubMedPubMedCentral

50.

Berr CM, Di Dalmazi G, Osswald A et al (2015) Time to Recovery of Adrenal Function After Curative Surgery for Cushing’s Syndrome Depends on Etiology. J Clin Endocrinol Metab 100:1300–1308. https://doi.org/10.1210/jc.2014-3632CrossRefPubMed

51.

Gad HEM, Ismail AM (2020) The role of vertebroplasty in steroid-induced vertebral osteoporotic fractures. Egypt Spine J 35:41–52. https://doi.org/10.21608/esj.2020.34844.1140CrossRef

52.

Vogel F, Braun LT, Rubinstein G et al (2020) Persisting Muscle Dysfunction in Cushing’s Syndrome Despite Biochemical Remission. J Clin Endocrinol Metab 105:e4490–e4498. https://doi.org/10.1210/clinem/dgaa625CrossRefPubMedCentral

53.

Vogel F, Braun L, Rubinstein G et al (2021) Patients with low IGF-I after curative surgery for Cushing’s syndrome have an adverse long-term outcome of hypercortisolism-induced myopathy. Eur J Endocrinol 184:813–821. https://doi.org/10.1530/EJE-20-1285CrossRefPubMed

54.

Andela CD, van Haalen FM, Ragnarsson O et al (2015) MECHANISMS IN ENDOCRINOLOGY: Cushing’s syndrome causes irreversible effects on the human brain: a systematic review of structural and functional magnetic resonance imaging studies. Eur J Endocrinol 173:R1–R14. https://doi.org/10.1530/EJE-14-1101CrossRefPubMed

55.

Bride MM, Crespo I, Webb SM, Valassi E (2021) Quality of life in Cushing’s syndrome. Best Pract Res Clin Endocrinol Metab 35:101505. https://doi.org/10.1016/j.beem.2021.101505CrossRefPubMed

56.

Starkman MN, Gebarski SS, Berent S, Schteingart DE (1992) Hippocampal formation volume, memory dysfunction, and cortisol levels in patients with Cushing’s syndrome. Biol Psychiatry 32:756–765. https://doi.org/10.1016/0006-3223(92)90079-FCrossRefPubMed

57.

McEwen BS, Gould EA, Sakai RR (1992) The Vulnerability of the Hippocampus to Protective and Destructive Effects of Glucocorticoids in Relation to Stress. Br J Psychiatry 160:18–23. https://doi.org/10.1192/S0007125000296645CrossRef

58.

van Aken MO, Pereira AM, Biermasz NR et al (2005) Quality of Life in Patients after Long-Term Biochemical Cure of Cushing’s Disease. J Clin Endocrinol Metab 90:3279–3286. https://doi.org/10.1210/jc.2004-1375CrossRefPubMed

59.

Zorumski CF, Paul SM, Izumi Y et al (2013) Neurosteroids, stress and depression: potential therapeutic opportunities. Neurosci Biobehav Rev 37:109–122. https://doi.org/10.1016/j.neubiorev.2012.10.005CrossRefPubMed

Title: Glucocorticoid Withdrawal Syndrome following treatment of endogenous Cushing Syndrome
Authors: Xin He
James W. Findling
Richard J. Auchus
Publication date: 26-04-2022
Publisher: Springer US
Keywords: Cushing's Syndrome
Endogenous Cushing's Syndrome
Glucocorticoid
Published in: Pituitary / Issue 3/2022
Print ISSN: 1386-341X
Electronic ISSN: 1573-7403
DOI: https://doi.org/10.1007/s11102-022-01218-y

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose:

Methods:

Results:

Conclusions:

Please log in to get access to this content

Other articles of this Issue 3/2022

Discrimination between non-functioning pituitary adenomas and hypophysitis using machine learning methods based on magnetic resonance imaging‑derived texture features

Regional genotypic variations in normosmic congenital hypogonadotropic hypogonadism: our experience and systematic review

Functioning gonadotroph adenomas in premenopausal women: clinical and molecular characterization and review of the literature

Endocrine disorders after primary gamma knife radiosurgery for pituitary adenomas: A systematic review and meta-analysis

Responsiveness to DDAVP in Cushing’s disease is associated with USP8 mutations through enhancing AVPR1B promoter activity

Growth hormone secreting pituitary adenomas show distinct extrasellar extension patterns compared to nonfunctional pituitary adenomas

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials